Lanadelumab: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes Recovery RCTs RCT mortality All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−7%

Mortality (1)−7%

RCTs (1)−7%

Late (1)−7%

00.511.5+

← Lanadelumab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Lanadelumab COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Amgen (DB RCT)−7%1.07 · 0.48–2.35death8/259/30COMMUNITY

Late treatment−7%1.07 · 0.48–2.358/259/307% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.88

All studies−7%1.07 · 0.48–2.358/259/307% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.8800.511.52+

Rotate screen for more detailsIncrease width for more details

← Lanadelumab
reduces riskLanadelumab
increases risk →

c19early.org

October 2026

Lanadelumab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Amgen (DB RCT)−7%1.07 · 0.48–2.358/259/30COMMUNITY

Late treatment−7%1.07 · 0.48–2.358/259/307% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.88

All studies−7%1.07 · 0.48–2.358/259/307% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.8800.511.52+

Rotate screen for more detailsIncrease width for more details

← Lanadelumab
reduces riskLanadelumab
increases risk →

c19early.org

October 2026

Lanadelumab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Amgen (DB RCT)−7%1.07 · 0.48–2.35death8/259/30COMMUNITY

Late treatment−7%1.07 · 0.48–2.358/259/307% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.88

All studies−7%1.07 · 0.48–2.358/259/307% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.8800.511.52+

Rotate screen for more detailsIncrease width for more details

← Lanadelumab
reduces riskLanadelumab
increases risk →

c19early.org

October 2026

Lanadelumab COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Amgen (DB RCT)24%0.76 · 0.35–1.67no disch.7/2511/30COMMUNITY

Late treatment24%0.76 · 0.35–1.677/2511/3024% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.51

All studies24%0.76 · 0.35–1.677/2511/3024% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.5100.511.52+

Rotate screen for more detailsIncrease width for more details

← Lanadelumab
reduces riskLanadelumab
increases risk →

c19early.org

October 2026

Lanadelumab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Amgen (DB RCT)−7%1.07 · 0.48–2.35death8/259/30COMMUNITY

Late treatment−7%1.07 · 0.48–2.358/259/307% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.88

All studies−7%1.07 · 0.48–2.358/259/307% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.8800.511.52+

Rotate screen for more detailsIncrease width for more details

← Lanadelumab
reduces riskLanadelumab
increases risk →

c19early.org

October 2026

Lanadelumab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Amgen (DB RCT)−7%1.07 · 0.48–2.358/259/30COMMUNITY

Late treatment−7%1.07 · 0.48–2.358/259/307% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.88

All studies−7%1.07 · 0.48–2.358/259/307% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.8800.511.52+

Rotate screen for more detailsIncrease width for more details

← Lanadelumab
reduces riskLanadelumab
increases risk →

c19early.org

October 2026

Lanadelumab COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Amgen (DB RCT)−7%1.07 · 0.48–2.35death8/259/30COMMUNITY Amgen (DB RCT)10%0.90 · 0.45–1.78no improv.9/2512/30COMMUNITY Amgen (DB RCT)24%0.76 · 0.35–1.67no disch.7/2511/30COMMUNITY Amgen (DB RCT)−9%1.09 · 0.56–2.14no recov.10/2511/30COMMUNITY

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Lanadelumab
reduces riskLanadelumab
increases risk →